GSK plc (GLAXF) Stock

About GSK plc

GSK plc, a global healthcare and pharmaceutical leader with roots tracing back to 1715, is headquartered in Brentford, United Kingdom. Operating extensively across the UK, United States, and other international markets, its activities span the entire lifecycle of healthcare products, encompassing research, development, manufacturing, and commercialization. Its broad portfolio includes pharmaceuticals, vaccines, over-the-counter medications, and a range of health-focused consumer products. The company operates through four primary divisions: Pharmaceuticals, Pharmaceutical Research & Development, Vaccines, and Consumer Healthcare. Within its pharmaceutical arm, GSK provides therapeutic solutions for a broad spectrum of conditions. These include ailments in respiratory health, HIV, immuno-inflammation, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital issues, metabolic diseases, bacterial infections, and dermatology. The consumer healthcare division delivers products across wellness, oral health, nutrition, and skin health categories. These are available in numerous formats, including nasal sprays, tablets, syrups, lozenges, gum and transdermal patches, caplets, infant syrup drops, liquid suspensions, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams, non-medicated patches, lip balms, gummies, and soft chews. GSK also maintains collaborative agreements with various organizations such as 23andMe, Lyell Immunopharma, Inc., Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc., Alector, Inc., and CureVac AG. Furthermore, strategic partnerships are in place with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The firm, known as GlaxoSmithKline plc until its name change to GSK plc in May 2022, embodies centuries of innovation in healthcare.

GSK plc (GLAXF) stock trades at $24.78 with a market capitalization of $99.29B. The stock is valued at a price-to-earnings (P/E) ratio of 17.83, price-to-book of 6.06, price-to-sales of 3.04. Over the past 52 weeks the stock has ranged between $18.85 and $31.48, and currently trades 21.3% below its 52-week high. It pays a dividend yielding 3.71%.

On profitability, GSK plc generates a return on equity (ROE) of 34.90% — well above the market average, a sign of a high-quality business, return on capital employed of 19.92%, an operating margin of 21.95%, a net profit margin of 17.50%.

In its most recent fiscal year, GSK plc reported annual revenue of $32.7B, net profit of $5.7B, revenue has compounded at -0.9% a year over the last five years, profit at -0.1% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 1.08, a current ratio of 0.82, total assets of $61.1B, $3.4B in cash and equivalents.

GLAXF has an average daily trading volume of 711 shares, a beta of 0.30 (less volatile than the overall market).

Official website: www.gsk.com